< Back

Design approaches for current and future HIV prevention efficacy trials

Virtual workshop series

October 2020 to May 2021

Hosted by The Global HIV Vaccine Enterprise in partnership with the HIV Vaccine Trials Network, the HIV Prevention Trials Network and the Forum for Collaborative Research.

HIV prevention is evolving rapidly with the roll out of new tools, such as pre-exposure prophylaxis (PrEP) and treatment as prevention, making a significant contribution towards controlling the epidemic. As a result, the design and conduct of the next generation of prevention trials is further affected by the outcomes of ongoing HIV prevention efficacy trials, including oral and injectable antiretrovirals, passively infused monoclonal antibodies and HIV vaccines.

This series of virtual workshops aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, which was held in Seattle by the Fred Hutch and the NIAID in November 2018. It led to a series of articles published in Statistical Communications in Infectious Diseases and a viewpoint in The Lancet HIV.

Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learnt for current HIV prevention designs. They will examine novel scientific approaches for establishing efficacy of new biologics in a future where all trial participants have access to effective prevention.

Introduction to the workshop (S1-01), Roger Tatoud, International AIDS Society, Geneva, Switzerland

S1-02: Setting the stage (S1-02), Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), Desmond Tutu HIV Centre, Cape Town, South Africa

Workshop programme

27 October 2020	Live session 1: Current efficacy trial design approaches – Challenges and lessons learned
6 November 2020	Live session 2A: Future design approaches for settings where all participants are on active prevention – ARV based prevention
18 November 2020	Live session 2B: Future design approaches for settings where all participants are on active prevention – Vaccines
25 February 2021	Live Session 3A: Novel Scientific Approaches for Establishing Efficacy of New Biologics
8 April 2021	Live session 2C: Future design approaches for settings where all participants are on active prevention – Monoclonal antibodies
27 April 2021	Panel Discussion 3B: Community engagement and involvement in clinical research Regulatory forum organized by the Forum for Collaborative Research

Organizing committee

Holly Prudden, International AIDS Society, Geneva, Switzerland
Holly Janes, Fred Hutchinson Cancer Research Center, Seattle, USA
Deborah Donnell, Fred Hutchinson Cancer Research Center, Seattle, USA
Stephaun Wallace, Fred Hutchinson Cancer Research Center, Seattle, USA
Veronica Miller, Forum for Collaborative Research, Berkeley, USA
Roger Tatoud, International AIDS Society, Geneva, Switzerland
Linda-Gail Bekker, Desmond Tutu HIV Centre, University of Cape Town, South Africa

For queries, please contact [email protected].

The organization of this workshop is supported by a grant from the Bill & Melinda Gates Foundation and the US National Institutes of Health (NIH).

This series of virtual events include pre-recorded presentations available before live panel sessions.

The programme was updated on 3 February 2021 to reflect trial results presented at HIV R4P // Virtual.